Market assessment of tuberculosis diagnostics in India in 2013
METHODS: Test volumes and unit costs were assessed for tuberculin tests, interferon-gamma release assays, sputum smear microscopy, serology, culture, speciation testing, nucleic-acid amplification tests (i.e., in-house polymerase chain reaction, Xpert® MTB/RIF, line-probe assays) and drug susceptibility testing. Data from the public sector were collected from the Revised National TB Control Programme reports. Private sector data were collected through a survey of private laboratories and practitioners. Data were also collected from manufacturers.
RESULTS: In 2013, India's public sector performed 19.2 million tests, with a market value of US$22.9 million. The private sector performed 13.6 million tests, with a market value of US$60.4 million when prices charged to the patient were applied. The overall market was US$70.8 million when unit costs from the ingredient approach were used for the 32.8 million TB tests performed in the entire country. Smear microscopy was the most common test performed, accounting for 25% of the overall market value.
CONCLUSION: India's estimated market value for TB diagnostics in 2013 was US$70.8 million. These data should be of relevance to test developers, donors and implementers.
Keywords: costs; diagnosis; tests; volumes
Document Type: Research Article
Affiliations: 1: Clinton Health Access Initiative CHAI: , New Delhi, India 2: Foundation for Innovative New Diagnostics FIND: , Geneva, Switzerland 3: UNITAID, Geneva, Switzerland 4: Independent consultant, currently consulting for FIND and UNITAID, Philadelphia, Pennsylvania, USA 5: Independent consultant, Zurich, Switzerland 6: Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands 7: McGill International TB Centre, Montreal, Quebec, Canada 8: McGill Global Health Programs, Department of Epidemiology & Biostatistics, McGill International TB Centre, 1020 Pine Ave West, Montreal, QC, Canada H3A 1A2. [email protected]
Publication date: 01 March 2016
The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.
The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content